Phase 1 study, condition: Obesity. The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant. Enrolment: 32 participants. Status: completed. No topline or peer-reviewed results are verified for publication on this Record for this study — registry facts only.
Checked 2026-08-08 · next review due 2026-11-08
← Back to the Record